Recombinant, Bivalent, Norovirus Vaccine Study

Condition:   Norovirus Interventions:   Biological: Norovirus GI.4 / GII.4 Bivalent VLP Vaccine (100 µg);   Biological: Norovirus GI.4 / GII.4 Bivalent VLP Vaccine (300 µg);   Drug: Placebo Sponsors:   Icon Genetics GmbH;   University Hospital, Ghent Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials